After an initial 4–6 weeks of intravenous amphotericin B, transition to an oral azole agent to complete a minimum of 12 months of therapy is recommended, with voriconazole the preferred option for ...

NurExone's ExoTherapy platform enables precise, minimally-invasive delivery of therapies to injured tissues using exosomes as an advanced delivery system. With a growing body of preclinical data and ...

Microglia can be engineered to detect disease-specific brain changes – like amyloid plaques in Alzheimer’s disease – and ...

Nonbenzodiazepine MRs may improve pain, muscle spasms, and physical outcomes compared with placebo in adults with acute LBP.

"Kyle's decades of financial, transactional and operational experience in our industry will make an immediate and positive ...

Major scientific discoveries can arise from simple decisions: say, by simply looking where virtually no one else has. Such ...

Have you heard of deep brain stimulation (DBS)? For certain neurological movement disorders like Parkinson’s disease, DBS is ...

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the central nervous system. The Westlake Village, California-based ...

Microglia were previously only detected in the brain and spinal cord, known as the central nervous system. This breakthrough ... It may also provide new drug targets for treating PNS hereditary ...

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments ...

A large-scale study published in Brain and Behavior has found that some widely used medications may have subtle but ...